Survival Analysis and Classification of Death in Patients under Antiarrhythmic Treatment

  • Hugo Ector
  • Hein Heidbüchel
  • Frans Van de Werf
Chapter
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 201)

Abstract

The practice of medicine is becoming increasingly complex and, paradoxically, despite greater knowledge, even more uncertain1. Today, knowledge itself is defined on the basis of an arbitrary but accepted statistical test, performed in a randomised clinical trial2. What the physician thinks, suspects, believes, or has a hunch about, is assigned to the “not-knowing” category. Technical advances, expected to reduce clinical uncertainty, have not only contributed to its increase, but have even been used to obscure it1. Obscurity and uncertainty are also promoted by the lack of statistical expertise of the average clinician and by the sophisticated, sometimes overtly unclear, presentation of trial results.

Keywords

Circulatory Failure Implantable Cardiac Defibrillator North American Society Antiarrhythmic Treatment Objective Data Analysis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Logan RL, Scott PJ. Uncertainty in clinical practice: implications for quality and costs of health care. Lancet 1996; 347: 595–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Hellman S, Hellman DS. Problems of the randomized clinical trial. N Engl J Med 1991; 324: 1585–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Ector H. Endpoints and trials: a matter of life and death. PACE 1994; 17: 1079–81.PubMedCrossRefGoogle Scholar
  4. 4.
    Ector H, Rogers R, Rubens A, De Geest H. Classification of death in patients under antiarrhythmic treatment. PACE 1993; 16: 2250–4.PubMedCrossRefGoogle Scholar
  5. 5.
    Epstein AE. AVID necessity. PACE 1993; 16: 1773–5.PubMedCrossRefGoogle Scholar
  6. 6.
    Gottlieb SS. Dead is dead — artificial definitions are no substitute. Lancet 1997; 349: 662–3.PubMedCrossRefGoogle Scholar
  7. 7.
    Lewis JA, Machin D. Intention to treat — who should use ITT? Br J Cancer 1993; 68: 647–50.PubMedCrossRefGoogle Scholar
  8. 8.
    Sackett DL, Gent M. Controversy in counting and attributing events in clinical trials. N Engl J Med 1979; 301: 1410–12.PubMedCrossRefGoogle Scholar
  9. 9.
    Epstein AE, Carlson MD, Fogoros RN, Higgins SL, Venditti FJ. Classification of death in antiarrhythmia trials. J Am Coll Cardiol 1996; 27: 433–42.PubMedCrossRefGoogle Scholar
  10. 10.
    Kim SG, Fogoros RN, Furman S, Connolly SJ, Kuck KH, Moss AJ. Standardized reporting of ICD patient outcome: the report of a North American Society of Pacing and Electrophysiology Policy conference, 9–10 February 1993. PACE 1993; 16: 1358–62.PubMedCrossRefGoogle Scholar
  11. 11.
    Echt DS, Liebson PR, Mitchell LB et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The cardiac arrhythmia suppression trial. N Engl J Med 1991; 324: 781–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Greene HL, Richardson DW, Barker AH et al. Classification of deaths after myocardial infarction as arrhythmic or nonarrhythmic (the cardiac arrhythmia pilot study). Am J Cardiol 1989; 63: 1–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Hinkle LE Jr, Thaler HT. Clinical classification of cardiac deaths. Circulation 1982; 65: 457–64.PubMedCrossRefGoogle Scholar
  14. 14.
    Rogers R, Ector H, Rubens A, Timmermans C, Heidbüchel H, De Geest H. Classification of death in patients under antiarrhythmic treatment. In: Aubert AE, Ector H, Stroobandt R, editors. Cardiac Pacing and Electrophysiology. Dordrecht: Kluwer; 1994: 41–8.CrossRefGoogle Scholar
  15. 15.
    Ector H. Endpoints and trials: a matter of life and death. Classification of death in patients under antiarrhythmic treatment. In: Oto AM, editor. Practice and Progress in Cardiac Pacing and Electrophysiology. Dordrecht: Kluwer; 1996: 1–5.CrossRefGoogle Scholar
  16. 16.
    The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. Boston: Little, Brown; 1973: 286.Google Scholar
  17. 17.
    Lown B, Wolf M. Approaches to sudden death from coronary heart disease. Circulation 1971; 44: 130–42.PubMedCrossRefGoogle Scholar
  18. 18.
    Lown B. Sudden cardiac death–1978. Circulation 1979; 60: 1593–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Passamani E. Clinical trials, are they ethical? N Engl J Med 1991; 324: 1589–92.PubMedCrossRefGoogle Scholar
  20. 20.
    Feinstein AR. The limitations of randomized trials. Ann Intern Med 1983; 99: 544–50.PubMedGoogle Scholar
  21. 21.
    Moss AJ, Hall WJ, Cannom DS et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996; 335: 1933–40.PubMedCrossRefGoogle Scholar
  22. 22.
    Cairns JA, Connolly SJ, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarizations: CAMIAT. Lancet 1997; 349: 675–82.PubMedCrossRefGoogle Scholar
  23. 23.
    Julian DG, Camm AJ, Frangin G et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997; 349: 667–74.PubMedCrossRefGoogle Scholar
  24. 24.
    Lee ET. Statistical Methods for Survival Analysis, 2nd edn. New York: John Wiley;1992.Google Scholar
  25. 25.
    Cox DR, Oakes D. Analysis of Survival Data. London: Chapman & Hall; 1992.Google Scholar
  26. 26.
    Whitehead J. The Design and Analysis of Sequential Clinical Trials, 2nd edn. Chicester; Ellis Horwood; 1992.Google Scholar
  27. 27.
    Gardner MJ, Altman DG. Statistics with Confidence. London: British Medical Journal, 1989.Google Scholar
  28. 28.
    Ector H, Jordaens L, Vanhaecke J. Survival analysis and clinical medicine. An observational comparison of the implantable cardioverter defibrillator, amiodarone treatment, and heart transplantation. Eur Heart J 1996; 17: 1444–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Yusuf S, Garg R, Zucker D. Analyses by the intention-totreat principle in randomized trials and databases. PACE 1991; 14: 2078–82.PubMedCrossRefGoogle Scholar
  30. 30.
    Fischer LD, Dixon DO, Herson J, Frankowski RK, Hearson MS, Peace KE. Intention to treat in clinical trials. In: Peace KE, editor. Statistical Issues in Drug Research and Development. New York: Marcel Dekker; 1990: 331–50.Google Scholar
  31. 31.
    Robin ED, Lewiston NJ. Type 3 and type 4 errors in the statistical evaluation of clinical trials. Chest 1990; 98: 463–5.PubMedCrossRefGoogle Scholar
  32. 32.
    Friedman PL, Stevenson WG. Unsustained ventricular tachycardia–to treat or not to treat,N Engl J Med 1996; 335: 1984–5.PubMedCrossRefGoogle Scholar
  33. 33.
    Mason JW. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med 1993; 329: 452–8.PubMedCrossRefGoogle Scholar
  34. 34.
    McCarthy M. Implantable cardiac defibrillators cut deaths. Lancet 1997; 349: 1225.CrossRefGoogle Scholar
  35. 35.
    Muschlin AI, Zipes DP. NASPE. 18th Annual Scientific Sessions, New Orleans, 7–10 May 1997.Google Scholar
  36. 36.
    Galbraith JK. Money. Whence it Came; Where it Went. New York: Bantam; 1975: 6.Google Scholar
  37. 37.
    Kassirer JP. Clinical trials and meta-analysis. What do they for us? N Engl J Med 1992; 327: 273–4.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1998

Authors and Affiliations

  • Hugo Ector
  • Hein Heidbüchel
  • Frans Van de Werf

There are no affiliations available

Personalised recommendations